Multicenter Analysis of Standard of Care versus Oxandrolone versus Testosterone in burn hypermetaboliSm (MASCOTS)

Clicks: 28
ID: 322711
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #46 of 94 articles by views in journal of burn care & research : official publication of the american burn association

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Severe burn injury results in a profound hypermetabolic state that complicates management and recovery. Oxandrolone has historically been used to help attenuate this response, but its withdrawal from the United States (US) market has led to increased use of alternative anabolic agents such as testosterone and human growth hormone. However, studies comparing the efficacy and safety between these alternative anabolic agents in adult burn patients remain limited. In this multicenter study, patients were stratified based on if they received testosterone, oxandrolone, human growth hormone, or no anabolic supplementation. Baseline characteristics and clinical outcomes were analyzed with ANOVA and Chi-square testing as appropriate. Propensity score matching was used to adjust for baseline differences in injury severity and patient characteristics. 813 patients who sustained major burn injuries between June 2022 and June 2025 across 12 verified US burn centers were analyzed. Anabolic supplementation was not associated with improved inpatient weight maintenance when compared with no anabolic supplementation (p=0.064), nor with differences in median weight change. Patients receiving anabolic therapy experienced longer hospital and intensive care unit stays (p=0.026). Overall mortality did not differ between treated and untreated patients (p = 0.885); however, mortality was higher among patients treated with oxandrolone compared with testosterone (p=0.001). Anabolic therapy was associated with higher rates of venous thromboembolic events (p = 0.019). These findings underscore that optimizing anabolic therapy will require balancing efficacy, safety, and economic considerations, with a focus on long-term functional outcomes beyond initial hospital stay.
Reference Key
openalex_W7171550029 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Aaron K Hong, Parker M Hannan, Anastasiya Ivanko, Denise Danos, Alexandra DeWitt Davis, Gina L. Defelice, Jonathan Schoen, Jeffrey E Carter, Janie Faris, Rebecca Coffey, Lauren Nosanov, Bo Hyun Kong, Megan Taylor Yoerg, Laura S. Johnson, Robel Beyene, Sarah V. Cogle, Anne Wagner, Arpana Jain, Kevin Foster, Hope Werenski, James H Holmes, David M Hill, Mahmoud Hassouba, Christopher R LaChapelle, Callie M Thompson, Adria Johnson, Rohit Mittal, Steven A. Kahn, Shawn Tejiram, Melissa M McLawhorn, Emma Blomberg, Justin Suarez, Shady N. Hayek, Allison N Boyd, M. Victoria P. Miles
Are you one of these authors? Claim your profile
Journal journal of burn care & research : official publication of the american burn association
Year 2026
DOI
10.1093/jbcr/irag127
URL
https://doi.org/10.1093/jbcr/irag127
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.